Table 1.
Analysis of selected human samples for polyomaviruses and HPyV9 with PCR
| Sample type | Source(s) | No. of samples tested | PyV detected (no. of samples) by generic PCRc | No. of samples HPyV9 positive by specific PCRc | HPyV9 genome amplified |
|---|---|---|---|---|---|
| Plasma | Kidney transplant recipientsa | 76 | BKV (5), MCPyV (1) | 1 | + |
| Patients with HIVb | 50 | MCPyV (1) | — | ||
| Immunocompromised adultsd | 25 | BKV (3) | — | ||
| Immunocompromised pediatric patientsd | 25 | BKV (2) | — | ||
| Serum | Patients with leukoencephalopathye | 47 | — | 1 | — |
| Kidney transplant recipientsa | 41 | HPyV9 (1) | 1 | + | |
| Urine | Kidney transplant recipientsa,f | 38 | BKV (6), MCPyV (1) | 1g | − |
| Immunocompromised patients with cancera | 26 | BKV (6), JCV (4), TSV (1) | — | ||
| Stem cell transplant recipientsa | 14 | BKV (6) | — | ||
| Patients with multiple sclerosish | 9 | JCV (2) | — | ||
| Othera | 92 | BKV (28), JCV (12), MCPyV (4), TSV (1) | — | ||
| Whole blood | Transplant recipientse | 20 | — | — | |
| Acute myeloid leukemia patient | 1 | — | 1 | — | |
| Bronchoalveolar lavage fluid | Patients with pneumoniae | 21 | MCPyV (1) | — | |
| Feces | Pediatric patients with gastroenteritis | 38 | — | — | |
| Cerebrospinal fluid | Patients with leukoencephalopathyi | 36 | — | — | |
| Othere | 38 | — | — |
a
Samples collected for BKV infection diagnosis.
b
Plasma with active cytomegalovirus infection.
c
—, PCR negative.
d
Samples collected for cytomegalovirus infection diagnosis.
e
Samples collected for herpesvirus infection diagnosis.
f
25 to 100 μl eluate from 10 to 30 ml urine (n = 27) or from 0.2 ml urine (n = 11).
g
From a patient with a double infection (MCPyV plus HPyV9).
h
From patients under natalizumab (Tysabri) therapy.
i
Samples collected for JCV infection diagnosis.